Quarterly report [Sections 13 or 15(d)]

SEGMENT REPORTING - Significant expense categories (Details)

v3.26.1
SEGMENT REPORTING - Significant expense categories (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating Expenses:    
Loss from operations $ (8,644,895) $ (7,460,095)
Other income 400,523 112,192
Consolidated Net Loss 8,244,372 7,347,903
Life science | Operating segment    
Operating Expenses:    
PMN310 development program costs 6,264,112 4,726,341
Other non-employee research and development costs 192,713 277,915
Employee costs 1,113,763 1,443,067
Other general and administrative costs 1,074,308 1,012,772
Loss from operations 8,644,895 7,460,095
Other income (400,523) (112,192)
Consolidated Net Loss $ 8,244,372 $ 7,347,903